Translational Biotechnology Fellowship at Galderma | aad.org

Translational Biotechnology Fellowship at Galderma

The new AAD Translational Biotechnology Fellowship is an opportunity for a dermatologist to advance science and explore career options within a pharmaceutical industry setting. The one-year fellowship provides a chance for a dermatologist to work in drug development and translational medical research at Galderma's facility in Sophia Antipolis, France.

Applications are being accepted for one fellowship beginning in fall 2014. The application period for the 2014 fellowship will end Oct. 15, 2013.

The Academy will provide the selected candidate with a $150,000 stipend to cover costs during the term of the fellowship, including but not limited to travel, housing, food, insurance, and other applicable costs and expenses. Galderma will contribute the necessary staff, materials, and resources to support and mentor the fellow. 

During the course of the one-year fellowship, the chosen candidate will participate in existing research and development activities and tasks that will span from research into product development, including, but not limited to, the following:

  • Interact with researchers in the creation of innovative concepts and with investigators who conduct proof-of-concept studies/proof-of-efficacy studies.
  • Assist in clinical development plans for dermatologic products, starting from initial clinical studies up to the submission of the registration dossier.
  • Assist in development of protocols for clinical studies and participate in setting up and monitoring studies, as well as in analyzing and interpreting the related data.
  • Participate/contribute to scientific and medical due diligence of in-licensing candidates.
  • Meet/interact with regulatory agencies (international and/or US as appropriate) during presentations of a drug's development plans.
  • Contribute to the development of scales in dermatology (for the assessment of disease severity and/or drug effect);
  • Be responsible, together with the Galderma safety officer, for the safety of subjects participating to clinical trials (by defining the Development Risk Management Plans, interacting with Independent Data Monitoring Committees, reviewing and assessing safety data collected in the clinical trials, etc.).

Applications will be reviewed and the fellow selected by a panel of members representing the Academy's Council on Science and Research, and Board of Directors. The following factors and criteria will be used by the selection panel when choosing the successful candidate:

  • Phase of training: Preference will be given to candidates who are in their last year of residency in an accredited American College of Graduate Medical Education dermatology residency program. To be considered, a candidate must be a physician member of the Academy who will have satisfactorily completed his/her residency by the time of the planned fellowship start date.
  • Willingness to relocate: To be selected, candidates must  be willing to relocate to France during the term of the fellowship.
  • Interest in research and industry: Candidates must be interested in research generally, pursuing research in an industry setting specifically, and exploring careers in industry.
  • Potential to contribute: The committee will consider candidates' likelihood to make significant contributions in drug development, in clinical trials development, in academic clinical and translational research, as a medical director in industry, as a  physician-entrepreneur involved in innovation, in drug/skin product regulation, or in nonprofit or governmental sectors.

To be considered for the 2014 fellowship, complete the online application by Oct. 15, 2013:

You are required to submit:

  • Letter of support from a current or recent supervisor/mentor (department chair, residency program director, fellowship mentor, or other similar position).
  • Current curriculum vitae.
  • A one-page personal statement describing why you want to pursue the fellowship and your future career plans.

Due date: Oct. 15, 2013